aTyr Pharma Inc (ATYR) News & EventsATYRNews & EventsaTyr Pharma Inc

aTyr Pharma Announces Q2 2026 Results and Restructuring

aTyr Pharma announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease, including pulmonary sarcoidosis and systemic sclerosis-related ILD. The program prioritization aims to focus the Company's resources on advancing its lead asset, efzofitimod, and targeted pipeline development to conserve capital in anticipation of receiving comments from the U.S. Food and Drug Administration on the protocol for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis, a major form of ILD. The Company submitted the protocol in June 2026 and is expecting feedback from the FDA by the end of August 2026. "We are proactively taking decisive, necessary action to focus our resources on our lead therapeutic candidate, efzofitimod, as we await feedback from the FDA on the protocol we submitted for our planned Phase 3 study in pulmonary sarcoidosis patients with restrictive lung disease. This approach positions aTyr to advance this planned Phase 3 study efficiently and continue completing the Phase 2 EFZO-CONNECT study in SSc-ILD," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "We remain confident in the potential of efzofitimod to become a meaningful therapy for patients with these forms of ILD, and these changes are essential to our ability to achieve that goal. We are deeply grateful to our dedicated team members for their outstanding contributions, commitment, and perseverance, including those who have helped advance tRNA synthetase biology over the years." Workforce reduction of approximately 60% will align organizational resources to support the efzofitimod program in ILD in anticipation of comments from the FDA on a protocol submitted for a planned Phase 3 study in pulmonary sarcoidosis and to complete the Phase 2 EFZO-CONNECT study in SSc-ILD. Jill Broadfoot, aTyr's Chief Financial Officer, will step down as of September 30, 2026, and transition to serve as a consultant to the Company. Brandon Yaras, aTyr's Vice President of Finance, will be appointed as CFO as of October 1, 2026. Nancy Denyes, aTyr's General Counsel, will step down as of September 30, 2026, and transition to serve as a consultant to the Company. The Company expects that this restructuring and additional cost saving measures will reduce annualized operating expenses by approximately $13M, beginning in the fourth quarter of 2026.

Company Cash Reserves Reach $58.9 Million, Expected to Sustain Operations Until Late 2028

Cash, cash equivalents, restricted cash and available-for-sale investments as of June 30, 2026, were $58.9 million. Based on its current cash and new operating expense forecast and plans, the Company anticipates that this cash position will be sufficient to fund the Company's current operations into late 2028. Future development of efzofitimod in the planned Phase 3 study in pulmonary sarcoidosis will require the Company to obtain additional capital through equity or debt offerings, grant funding, collaborations, strategic partnerships and/or licensing arrangements.

Major Averages Close Broadly Lower as Oil Prices Jump Again

The major averages closed broadly lower, giving back some of yesterday's gains as tech stocks lagged, U.S. Treasury yields rose, and oil prices jumped once again. A meeting between President Donald Trump and Chinese President Xi Jinping has ended, with investors concerned that the summit resulted in no major policy breakthroughs.Brent crude pushed above $104 a barrel as the Iran conflict and ongoing Strait of Hormuz disruptions continue pressuring global energy supplies. Rising oil prices are now feeding into inflation expectations, transportation costs, and consumer spending concerns as markets increasingly fear a stagflationary setup.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applied Materialsreportedand raised its 2026 equipment growth estimateFigmaprovided areport for Q1Gemini Space Stationannounced that Winklevoss Capital Fund made aBlackstoneand CD&R are both in the early stages of exploring bids for Magnum Ice Cream,MasterCardand JD.com2. WALL STREET CALLS:Arista Networksto Outperform at Raymond JamesRBCTexas Roadhouseon better beef prices, traffic growthCiscoto Buy at HSBC on stronger AI infrastructure momentumViking Holdingsto Equal Weight at Morgan StanleyFermito In Line at Evercore ISI3. AROUND THE WEB:BPplans to wind down much of its pipeline gas trading team, eliminating about 20 roles and integrating the remaining staff into its expanding LNG trading business. Reuters reportsFinal bids are in for Estee Lauderbrands Too Faced, Smashbox, and Dr. Jart, and the process could be completed in a matter of weeks, WWD reportsAs Metaprepares to lay off about 10% of its staff on May 20 as part of ongoing efficiency efforts and investment rebalancing, adding to prior rounds of layoffs, sources say morale is low, Wired reportsGoogleis planning to announce a new Gemini model at it's I/O conference, with the release expected to land around the class of OpenAI's GPT-5.5 and short of Anthropic's Mythos, Sources reportsStarbucksis undertaking another round of corporate restructuring, including about 300 U.S. job cuts and a review of its international corporate workforce, CNBC says4. MOVERS:Globantrises afterRXOhigher after Stifelthe stock to BuyDexComgains after announcing aYork Space Systemslower afterand provided guidance for FY26DLocaland ARS Pharmaceuticalsfalls after5. EARNINGS/GUIDANCE:Datavault, with EPS and revenue higher year-over-yearRBC Bearingsand provided guidance for Q1Enveric Biosciences, with CEO Joseph Tucker commenting "Our progress in the first quarter of 2026 reflects continued execution against our core mission"aTyr Pharma, with CEO Sanjay Shukla commenting, "2026 is off to a productive start"Mako Mining, with EPS and revenue higher year-over-yearINDEXES:The Dow fell 537.29, or 1.07%, to 49,526.17, the Nasdaq lost 410.08, or 1.54%, to 26,225.15, and the S&P 500 declined 92.74, or 1.24%, to 7,408.50.